Degrader conjugates and tissue targeting at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

6 organizations at TPD Summit 2026 present work in degrader conjugates & tissue targeting: 5 drug developers and 1 technology or service provider. Between them they bring 8 presentations to the program. Most represented: AstraZeneca (2 on the program), Pallando Therapeutics (1 on the program), Ajinomoto Bio-Pharma Services (1 on the program). As of Oct 8, 2026.

All 95 organizations at TPD Summit 2026 →

Showing 1–6 of 6 organizations

Organization	TPD Summit 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases.	Talk Wed Oct 28 2:30pm Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling Track A: Discovery AI & computational design Talk Thu Oct 29 9:30am Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs) Future of Induced Proximity Track Degrader conjugates & tissue targeting
Pallando Therapeutics
pallandotx.com Biotech Biotech developing targeted protein degraders.	Chair Thu Oct 29 8:20am Part of Developing Next-Generation Degraders to Achieve Tissue-Specific Protein Degradation & Enable Development of Clinically Impactful Therapies Chair’s Opening Remarks Future of Induced Proximity Track Degrader conjugates & tissue targeting Chair Thu Oct 29 2:45pm Part of Expanding the Therapeutic Horizon of Induced Proximity Modalities for Immunology, Neuroscience & Beyond to Bring Effective Treatment Options to More Patients Chair’s Closing Remarks Future of Induced Proximity Track Degrader discovery & design
Ajinomoto Bio-Pharma Services San Diego, CA	◇Program Partner
ajibio-pharma.com CROs & CDMOsProgram Partner CDMO offering site-specific conjugation (AJICAP, built on Fc-affinity peptides) and linker technology, applied here to antibody-delivered degraders.	Talk Wed Oct 28 1:00pm Enabling Next-Generation Targeted Protein Degradation through AJICAP® Site-Specific Conjugation and Linker Technologies Track A: Discovery Degrader conjugates & tissue targeting
Montara Therapeutics
montaratx.com Biotech Neuroscience biotech designing brain-selective medicines for neurological diseases to improve safety and efficacy.	Talk Thu Oct 29 11:45am BrainTACs Enable Brain-Selective Inhibition of CNS Targets, with Reduced Peripheral Adverse Effects Future of Induced Proximity Track Induced proximity beyond degradationDegrader conjugates & tissue targeting
Orum Therapeutics
orumrx.com Biotech Develops degrader-antibody conjugates that deliver targeted protein degraders into specific cell types.	Talk Thu Oct 29 9:00am Next-Generation Degrader Antibody Conjugates Future of Induced Proximity Track Degrader conjugates & tissue targeting
Pfizer New York, NY
pfizer.com Large pharma Pharmaceutical company developing and marketing medicines and vaccines across oncology, vaccines, internal medicine and other areas.	Talk Thu Oct 29 8:30am Degrader-Antibody Conjugates: Proof of Concept Through Design of a Potent BRD4 Degrading Linker-Payload Future of Induced Proximity Track Degrader conjugates & tissue targeting